RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Adaptimmune Therapeutics - Stock

Adaptimmune Therapeutics Stocks 2024

Adaptimmune Therapeutics Stocks

1.21 B

Ticker

ADAP

ISIN

US00653A1079

WKN

A14SUX

In 2024, Adaptimmune Therapeutics had 1.21 B outstanding stocks, a 0% change from the 1.21 B stocks in the previous year.

The Adaptimmune Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e1.21
2028e1.21
2027e1.21
2026e1.21
2025e1.21
2024e1.21
20231.21
20220.97
20210.93
20200.85
20190.63
20180.58
20170.53
20160.42
20150.42
20140.42
20130.42
20120.42

Adaptimmune Therapeutics shares outstanding

The number of shares was Adaptimmune Therapeutics in 2023 — This indicates how many shares 1.206 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Adaptimmune Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Adaptimmune Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Adaptimmune Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Adaptimmune Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Adaptimmune Therapeutics Aktienanalyse

What does Adaptimmune Therapeutics do?

Adaptimmune Therapeutics PLC is a biotechnology company specializing in the development of immunotherapies against cancer. The company was founded in 2008 and is headquartered in Oxfordshire, England. Adaptimmune focuses on harnessing the human immune system to target and destroy cancer cells. The company's business model primarily revolves around the research and development of therapeutic products for different types of cancer. It develops and utilizes T-cell receptor (TCR) therapies to specifically target cancer cells. TCRs are proteins on T-cells that can recognize and kill cancer cells. Adaptimmune harnesses this property of TCRs to develop specific receptors targeted against certain types of cancer. Adaptimmune has three different business segments: oncology, autoimmune diseases, and infections. However, the focus is primarily on oncology. In this area, Adaptimmune concentrates on developing TCR products for various types of cancer such as pancreatic cancer, esophageal cancer, and lung cancer. One of Adaptimmune's key products is the T-cell therapy known as SPEAR (Specific Peptide Enhanced Affinity Receptor), which is individually developed for each patient. This therapy utilizes TCRs targeting specific tumor cells. The TCRs are optimized so that the body's own T-cells can precisely recognize and destroy the cancer cells. SPEAR has already shown promising results in a clinical study for melanoma patients. Another important product of Adaptimmune is ADP-A2M4. This immunotherapy also utilizes TCRs developed to target specific cancer cells. ADP-A2M4 is currently in Phase II clinical trials for advanced or metastatic esophageal cancer or gastric cancer. Adaptimmune also has partnerships with other companies and organizations such as GSK, NY-ESO-1, Universal Cells, and the MD Anderson Cancer Center. This collaboration expands the company's portfolio and enables the development of innovative immunotherapies. Overall, Adaptimmune's goal is to develop innovative TCR products for the treatment of various types of cancer. With its focus on immunotherapies, the company has created unique solutions to mobilize the human immune system specifically against cancer. Adaptimmune has the potential to revolutionize cancer treatment and improve the lives of millions of people. Adaptimmune Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Adaptimmune Therapeutics's Shares Outstanding

Adaptimmune Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Adaptimmune Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Adaptimmune Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Adaptimmune Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Adaptimmune Therapeutics Stock

How many stocks are there of Adaptimmune Therapeutics?

The current number of stocks of Adaptimmune Therapeutics is 1.21 B undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Adaptimmune Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Adaptimmune Therapeutics evolved in recent years?

The number of shares of Adaptimmune Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Adaptimmune Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Adaptimmune Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Adaptimmune Therapeutics pay?

Over the past 12 months, Adaptimmune Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adaptimmune Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Adaptimmune Therapeutics?

The current dividend yield of Adaptimmune Therapeutics is .

When does Adaptimmune Therapeutics pay dividends?

Adaptimmune Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adaptimmune Therapeutics?

Adaptimmune Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Adaptimmune Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adaptimmune Therapeutics located?

Adaptimmune Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adaptimmune Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adaptimmune Therapeutics from 7/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/1/2024.

When did Adaptimmune Therapeutics pay the last dividend?

The last dividend was paid out on 7/1/2024.

What was the dividend of Adaptimmune Therapeutics in the year 2023?

In the year 2023, Adaptimmune Therapeutics distributed 0 USD as dividends.

In which currency does Adaptimmune Therapeutics pay out the dividend?

The dividends of Adaptimmune Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Adaptimmune Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Adaptimmune Therapeutics

Our stock analysis for Adaptimmune Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adaptimmune Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.